ArticleBreast (Edinburgh, Scotland)2026

A nationwide population-based study on the incidence and prognosis of HER2-positive breast cancer eligible for adjuvant pertuzumab in the modern era of neoadjuvant therapy.

Antonis Valachis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.